{"id":"NCT03406078","sponsor":"AstraZeneca","briefTitle":"Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma","officialTitle":"A Multicentre, Randomized, Double-Blind, Placebo Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma (SOURCE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-03-05","primaryCompletion":"2020-09-25","completion":"2020-09-25","firstPosted":"2018-01-23","resultsPosted":"2021-12-09","lastUpdate":"2021-12-09"},"enrollment":150,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Asthma"],"interventions":[{"type":"BIOLOGICAL","name":"Tezepelumab","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tezepelumab","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma","primaryOutcome":{"measure":"Categorized Percent Reduction From Baseline in the Daily OCS Dose While Not Losing Asthma Control","timeFrame":"Baseline to Week 48","effectByArm":[{"arm":"Tezepelumab","deltaMin":40,"sd":null},{"arm":"Placebo","deltaMin":35,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.434"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":60,"countries":["United States","Argentina","Germany","Poland","South Korea","Turkey (TÃ¼rkiye)","Ukraine"]},"refs":{"pmids":["36702146","35364018","33050928"],"seeAlso":["https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00009&amp;attachmentIdentifier=1c64c2ac-dfb7-45d2-8049-e1f6f24c70ed&amp;fileName=d5180c00009-csp-v4_(14-May-2020).pdf&amp;versionIdentifier=","https://filehosting-v2.pharmacm.com/api/Attachment/Download?tenantId=80217111&amp;parentIdentifier=D5180C00009&amp;attachmentIdentifier=8bc47970-3cdb-4463-8948-393d1ca86f50&amp;fileName=d5180c00009-sap-ed-3_(22-Oct-2020).pdf&amp;versionIdentifier="]},"adverseEventsSummary":{"seriousAny":{"events":12,"n":74},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Asthma","Bronchitis bacterial","Headache"]}}